Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Recordati SpA
Newly published data and results presented at ESMO for Amgen’s sotorasib (AMG 510) show relatively long-lasting responses and progression-free survival in lung cancer.
The European Medicine Agency has recommended extending the therapeutic indication of a raft of drugs that are already authorized in the EU.
Deal Snapshot: The firms are partnering on a digital therapeutic for schizophrenia in a deal potentially worth $500m.
European Commission approval of Fortacin as OTC premature ejaculation treatment makes it only the fifth drug switched EU-wide through the centralized procedure.
- OTC, Consumer
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Bouchara Recordati
- Dr. F. Frik Ilaç A.S.
- Opalia Pharma S.A.
- Orphan Europe
- Recordati Pharmaceuticals Ltd.
- Laboratorios Casen Fleet
- Italchimici S.p.A.
- Pro Farma AG
- Recordati S.A. Chemical and Pharmaceutical Company
- Recordati Rare Diseases Canada Inc.
- Natural Point S.r.l.
- Tonipharm S.A.S.